Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868799 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14447247 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL15592462 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL10136513 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL11295143 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL10289797 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14473782 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14072902 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL17628741 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14072906 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4606925-A | Flavoring with alkyl-substituted cyclohexyl and cyclohexenyl carboxylic acids | GIVAUDAN CORPORATION (US) | 1986-08-19 | — | — | US | claimed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2016106624-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-1243572-B1 | PROCESS FOR THE PREPARATION OF CYCLOHEXANOL | ASAHI CHEMICAL IND (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2009106980-A2 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-6552235-B2 | Catalyzing hydration reaction of cyclohexene with water using a solid catalyst in a solvent to increase the yield | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030018223-A1 | Process for the preparation of cyclohexanol | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1243572-A1 | PROCESS FOR THE PREPARATION OF CYCLOHEXANOL | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | HAVCR2, FURIN, SARS1 | SLC1A2 4251/4885SLC1A1 3644/4885EPHX1 1098/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | SLC1A2 4103/4885SLC1A1 4102/4885EPHX1 714/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | SLC1A2 4464/4885SLC1A1 4205/4885EPHX1 891/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SLC1A2 4759/4885SLC1A1 4345/4885EPHX1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.